Analysis on the Use of Antibacterial Drugs Under the Centralized Drug Procurement Policy&#x02014;&#x02014;Taking a Tertiary Hospital in Zhejiang Province as an Example

doi:10.19546/j.issn.1674-3830.2024.11.012

China Health Insurance ›› 2024, Vol. 0 ›› Issue (11) : 96-102. DOI: 10.19546/j.issn.1674-3830.2024.11.012

Analysis on the Use of Antibacterial Drugs Under the Centralized Drug Procurement Policy——Taking a Tertiary Hospital in Zhejiang Province as an Example

Author information +

History +

Abstract

Objective: The paper analyzes the use of antibacterial drugs in a tertiary hospital of Zhejiang Province under the centralized drug procurement policy, in order to provide a reference for the rational clinical use of antibacterial drugs and the orderly promotion of centralized procurement. Methods: We extract data on the use of antibacterial drugs before and after the implementation of the centralized drug procurement policy from the hospital information system, analyze indicators such as defined daily doses, defined daily dose cost, cost savings, and generic drug substitution rate, and explore the impact of the policy on the clinical use of antibacterial drugs. Results: After the implementation of the centralized drug procurement policy, defined daily doses of various types of antibacterial drugs have increased or decreased to varying degrees, and defined daily dose cost has shown an overall downward trend. The average potential cost savings are 590600 yuan one year, and the utilization rate of selected drugs reaches 85.31%. The substitution rate of generic drugs has increased from 33.21% to 83.18%. Conclusion: The centralized procurement of antibacterial drugs has optimized the medication structure, and reduced the economic burden on patients. From the perspective of clinical pharmacists, it is recommended to further strengthen the monitoring and management of antibacterial drugs, and steadily promote the normalization of policies.

Key words

centralized drug procurement policy / antibacterial drugs / defined daily doses / defined daily dose cost

Cite this article

EndNote

Ris (Procite)

Bibtex

Download Citations

Analysis on the Use of Antibacterial Drugs Under the Centralized Drug Procurement Policy——Taking a Tertiary Hospital in Zhejiang Province as an Example[J]. China Health Insurance. 2024, 0(11): 96-102 https://doi.org/10.19546/j.issn.1674-3830.2024.11.012

References

[1] 谭清立,郭润镒,孙慧琳,等.药品集中带量采购与医保谈判政策的协同作用[J].中国药房,2021,32(15):1793-1799.
[2] 汤少梁,陈蕾,成彦.国家药品集中带量采购政策对住院患者医疗费用的影响研究[J].中国卫生经济,2024,43(1):38-43.
[3] XINGQ, TANG W, LI M, et al.Has the volume-based drug purchasing approach achieved equilibrium among various stakeholders? evidence from China[J]. International journal of environmental research and public health, 2022,19(7).
[4] 康学英,李学粉,于蕾.药品集中带量采购政策在内蒙古某三甲中医院实施后的药品使用情况及经济学效果[J].中国药物经济学,2023,18(06):33-38.
[5] 段凤然,文小桐,刘雨欣,等.国家药品集中带量采购政策下抗肿瘤药品使用特征分析[J].中国医疗保险,2023(05):104-109.
[6] 董雅芬,邱彦,金辉,等.胰岛素集中带量采购后我院胰岛素类药品的使用情况分析[J].中国药房,2023,34(18):2278-2282.
[7] 钟淇滨. “4+7”带量采购政策对某院胰岛素类药物的使用情况分析[J].海峡药学,2024,36(02):83-86.
[8] 屈茹楠,高岸,范国荣,等.国家带量采购政策对上海某院原研和仿制降压药使用状况的影响[J].中国药业,2022,31(15):10-15.
[9] 岳小林,付娜,赵艳玲,等.国家集中带量采购中选药品疗效与安全性的真实世界研究[J].临床药物治疗,2022,20(6):43-48.
[10] 过佳月,陈大宇,张海霞.集中带量采购政策相关的口服抗菌药物使用量及费用的中断时间序列分析[J].药学与临床研究,2023,31(04):374-379.
[11] 向左娟,陈小娟,胡晓杰,等.药品集中带量采购后某院抗菌药物使用及细菌耐药率变迁情况[J].中南药学,2022,20(11):2678-2683.
[12] PANG YY, MA CL.Real-world pharmacological treatment patterns of patients with threatened miscarriage in China from 2014 to 2020: a cross-sectional analysis[J]. Journal of clinical pharmacy and therapeutics, 2022,47(2):228-236.
[13] 张金玲,陈辉.药品集中带量采购对我院降压药使用情况的影响[J].湖北科技学院学报(医学版),2023,37(2):145-150.
[14] 李大双,颜建周,白铭钰,等.抗菌药物实施国家集中带量采购的政策效果分析[J].中国卫生经济,2023,42(5):17-21.
[15] 童荣生,赵杰,王明贵,等.医疗机构抗菌药物集中带量采购管理专家共识[J].医药导报,2023,42(01):1-5.
[16] 王之舟,董宪喆,白向荣,等.口服抗菌药物集中带量采购实施情况问卷调查分析[J].中国医院药学杂志,2023,43(13):1506-1511.
[17] 林燕铭,周娜,韩汶静,等.药品集中带量采购政策对药品利用与支出的影响分析[J].中国卫生经济,2022,41(9):13-18.
[18] 郭丽,王健,王敬毅,等.药品集中采购政策对医院抗菌药物使用的影响研究[J].卫生经济研究,2022,39(6):24-29.
[19] 洪笃云,欧阳炜,董玉娟,等.国家药品集中采购政策对抗菌药物用量迁移的影响[J].中国药物经济学,2023,18(12):26-30.
[20] YANG Y, CHEN L, KE X, et al.The impacts of Chinese drug volume-based procurement policy on the use of policy-related antibiotic drugs in Shenzhen, 2018-2019: an interrupted time-series analysis[J]. BMC Health Services research, 2021,21(1):668.
[21] 郑聃. 药品带量采购政策患者满意度及其影响因素分析[J].中国医药导刊,2022,24(06):623-628.